Before choosing a Found plan, the most consequential question may be what happens if the treatment you want is not the treatment you are offered. Found’s refund terms distinguish disqualification from every available option from disqualification from a preferred medication. That distinction matters when enrollment precedes a final prescribing decision. The company offers a broader weight-management service—not simply access to one GLP-1—and its financial obligations can continue even when a member does not receive the particular drug they expected.
This review examines Found’s public documentation consulted October 19, 2026, with emphasis on enrollment, ongoing charges and responsibility when plans change. Found describes personalized online care, branded and compounded medications, oral alternatives, coaching and digital support. It also publishes unusually detailed pricing tables. Yet those tables do not resolve every question: advertised annual prepayment sits alongside four-week billing language, Medicare messaging differs from general insurance exclusions, and the membership refund policy contains wording that needs clarification before purchase.
At a glance
- Compounded-plan billing
- Published semaglutide and tirzepatide plan rates use 28-day cycles; the pricing page conditions its lowest advertised rates on 12-month plans paid upfront.
- Preferred medication is not guaranteed
- Being ineligible for a preferred GLP-1 does not qualify a member for a refund if other Found treatment options remain available.Sources: [8]
- Renewals and notice
- Renewal payments are nonrefundable. Found recommends canceling or pausing at least 48 hours before the scheduled renewal.Sources: [8]
- Insurance does not cover every component
- Found’s billing consent makes members responsible for compounded GLP-1 charges and treats the subscription fee as a noncovered service.Sources: [12]
- Brand-name plan excludes medication
- The branded GLP-1 plan includes prescription services and membership, but medication is billed separately; eligible NovoCare and LillyDirect fulfillment is cash-pay only.Sources: [8]
Enrollment purchases a program, not a particular prescription
Found describes itself as an online weight-loss program offering personalized care. Its billing consent identifies affiliated medical groups, including Pippen entities, rather than treating the platform and clinical practice as interchangeable. Found says every clinician is board-certified and trained in metabolic medicine; that is a company statement, not independently verified credentialing. The practical contract question is which entity provides clinical care, which collects membership charges and which handles a disputed bill.
The compounded semaglutide pathway starts with a health assessment and clinician review of medical history, previous efforts and personal circumstances. A prescription depends on clinical appropriateness. Found’s compounded tirzepatide page describes adults with obesity or overweight, a BMI of at least 25 and at least one weight-related condition. Those are that page’s stated criteria, not a universal eligibility rule or assurance that an applicant will receive treatment.
Found also offers non-GLP-1 oral medication plans and distinguishes obesity-approved medicines from medicines approved for other conditions that may be prescribed off-label. This breadth matters financially: medical disqualification from all options can support a membership refund, but rejection of a preferred drug does not if alternatives remain. Before purchasing, use these enrollment-term questions to establish what happens if the clinician proposes a different medication or no medication.
The refund window needs a written interpretation
Found’s policy first states that a full membership-fee refund is available if either condition applies: cancellation within three days of the original purchase, or cancellation before completing the first medical consultation. It then says that after “either of these events” occurs, the fee becomes nonrefundable. That follow-on sentence makes the interaction between the two protections unclear. A reader should not assume that an unused account, by itself, preserves refund eligibility.
Ask Found to apply the policy to concrete dates before paying: what if the consultation occurs on day one, or has not occurred by day four? Also ask how the rule applies to a prepaid multimonth plan. The consulted documentation does not establish whether unused prepaid periods are refundable after the initial window. The separate medication rule is firmer: medications and laboratory kits cannot be returned or refunded once dispensed or shipped, even if unused.
Cancellation, a refund request and stopping a pharmacy order are therefore different actions. Found says renewal payments are nonrefundable and recommends canceling or pausing at least 48 hours before the scheduled renewal. Its stated refund timeframe can be up to 30 days; that should not be treated as guaranteed bank receipt within that period. The key refund boundaries are the membership’s eligibility window, the renewal charge and the medication’s dispensing or shipping status.
Read the plan term separately from the payment interval
Found’s compounded-plan terms describe an all-in price covering clinical care, medication and membership, billed every four weeks. The table below preserves that 28-day interval rather than relabeling it a calendar month. Separately, the commercial pricing page says its advertised starting prices are based on 12-month plans paid upfront. These statements do not establish one unambiguous collection schedule. Obtain the actual checkout amount and future charge dates for the specific plan you select.
The terms’ other plan tables label one, three, six and 12 months as four, 12, 24 and 48 weeks. A 48-week period is not a calendar year. Nor does a plan’s stated duration establish the medication quantity in each shipment. Found’s documentation leaves the relationship between upfront collection, four-week charges and the full contractual commitment insufficiently clear. This is precisely where a monthly-price versus commitment check is useful.
New members choosing a one-month compounded plan receive a separate introductory discount. Semaglutide is $99 initially, then $199 per cycle with insurance, or $179 initially, then $289 cash-pay. Tirzepatide is $149 initially, then $289 with insurance, or $219 initially, then $359 cash-pay. These are introductory and subsequent charges, not continuing promotional rates. Applicable laboratory testing and branded GLP-1 medication are excluded from the compounded plan.
| Stated plan term | Compounded semaglutide: insurance / cash | Compounded tirzepatide: insurance / cash |
|---|---|---|
| 1 month | $199 / $289 | $289 / $359 |
| 3 months | $159 / $249 | $239 / $309 |
| 6 months | $129 / $219 | $209 / $289 |
| 12 months | $99 / $169 | $179 / $239 |
Insurance pricing leaves several responsibilities with the member
The phrase “with insurance” needs careful interpretation at Found. The terms say the reduced price reflects coverage for clinical care, with copays, coinsurance and deductibles potentially applying. The billing consent separately makes the member financially responsible for compounded GLP-1 medication and prohibits submitting those charges to insurance. It also describes the Found subscription as a noncovered service. The insurance rate is therefore not evidence that an insurer pays for the compounded preparation.
Insurance also changes the service process. Found says synchronous video visits are required, including before each refill, and are billed through insurance at the member’s visit copay—typically around $30—in addition to the plan price. Cash-pay care is text-based and asynchronous in most cases, without a separate visit copay. A missed scheduled consultation, or cancellation with less than 24 hours’ notice, carries a $30 fee under the billing consent.
Post-claim balances can generate later charges: Found provides an invoice due within 15 days, then charges the card on file if unpaid. An unsuccessful payment leaves another 30 days to resolve the balance before subscription termination. Found’s free coverage checker can report medication-specific coverage, prior authorization and available cost estimates, but it neither requests treatment nor issues prescriptions. Confirm consultation coverage and medication coverage separately, rather than treating the checker as a complete enrollment quote.
Brand-name and oral plans have different inclusions
Found’s branded GLP-1 plan includes prescription services and membership, not the medication itself. Its insurance rates for one-, three-, six- and 12-month terms are $89, $79, $69 and $49 per 28-day cycle; cash-pay rates are $149, $139, $129 and $99. The non-GLP-1 oral generics plan lists those same rates and intervals but includes medication as well as prescription services and membership. Matching prices do not mean matching benefits.
The medication catalog separately lists Ozempic at $1,100 per month, Wegovy from $650 per month-plus, Zepbound from $650 per month-plus and Mounjaro at approximately $1,100 per month. That block does not establish supply quantities or complete conditions. Other comparison material gives lower cash-pay, multimonth figures for Wegovy and Zepbound without fully explaining presentation or channel differences. A brand name alone is consequently insufficient to identify the applicable medication price.
Brand-name medication may be filled at a pharmacy of the member’s choice using cash or insurance, or, where eligible, through cash-only NovoCare or LillyDirect pathways. Found also advertises a one-time $100 initial-checkout discount for cash-pay memberships supporting specified branded prescriptions and $50 when Found is in-network. Med Kit plans are excluded; offers may change. These discounts apply to that checkout, not every renewal, and do not turn separately billed medication into an included benefit.
Medicare messaging is not reconciled with the general exclusions
Found’s general offer terms exclude people with government insurance, including Medicare, Medicaid, TriCare and MediCal, from the insurance-priced offering. A separate Medicare page, however, advertises care for adults ages 65–75 and conditional access to a Medicare GLP-1 Bridge. Neither page fully explains how that pathway interacts with the general exclusion. Prospective members should seek a plan-specific written answer rather than assuming either that Medicare is universally accepted or that every Medicare-related service is unavailable.
According to Found’s Medicare page, the Bridge runs July 1, 2026, through December 31, 2027, outside the ordinary Part D payment flow. It describes a $50 monthly medication copay for qualifying Part D members with an eligible weight-management prescription, separate from Found membership. Found says that copay does not count toward the Part D deductible or out-of-pocket maximum and that low-income subsidies do not apply. The page expressly does not guarantee coverage.
That page lists Wegovy injections and tablets, Zepbound KwikPen and Foundayo as products within its description of the program, subject to updates. It also presents compounded starting prices differently from the main plan tables, describing semaglutide from $99 and tirzepatide from $179 as cash-pay with membership separate. Those figures should not be merged with the main tables into a single offer. Request the product, presentation, membership fee, medication charge and applicable eligibility rules together.
Follow-up is documented, but logistics remain less specific
Found’s compounded plan lists a metabolic assessment, access to weight-management clinicians, compounded medication, one-to-one coaching, app-based lifestyle tools and community access. Its tirzepatide page describes monthly follow-up to review response and address problems. The semaglutide page promises instruction on injection, storage and disposal, plus messaging between visits. These are meaningful service descriptions, but permission to message at any time is not a promise of immediate clinical response or continuous human availability.
The pricing page also includes 24/7 access to Aimee, an AI health companion. That should be distinguished from clinician support. Found says eligible members receive medication at home and most can start treatment within a week; this is not a guaranteed delivery date or a separate shipping estimate. Public documentation does not settle shipping fees, carrier, package quantities, cold-chain procedures or distinct timelines for clinical review, dispatch and arrival.
For compounded semaglutide, Found says it works exclusively with 503A pharmacies and that medication undergoes third-party potency, purity and sterility testing before shipment. These are provider claims; the consulted material does not identify the pharmacies, testing laboratory or certificates of analysis. Availability also varies by state without a definitive product-by-product list. A written map of provider responsibilities should identify who handles prescribing questions, pharmacy problems, delivery concerns and membership billing.
Contract clarity does not establish clinical outcomes
Found advertises compounded semaglutide as a weekly subcutaneous injection and compounded tirzepatide as a weekly injection. It also markets an injectable compounded semaglutide “microdosing” program, whose full pricing and admission criteria are not established in the consulted documentation. Found’s own disclaimer says compounded GLP-1s are not FDA-reviewed for safety, efficacy or quality and are not approved to treat a specific condition. A separate marketing pathway does not establish a separate body of clinical evidence.
FDA guidance explains that compounded preparations are not FDA approved and do not undergo the agency’s premarket review. FDA recommends their use when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, nor do Found’s testing claims prove equivalence. Approval attaches to a specific drug product, not to Found as a platform or to its pharmacy relationships.
FDA also advises not using an injectable GLP-1 that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. This is an important responsibility to settle before shipment. More broadly, NIDDK describes medication selection as a discussion of benefits, side effects, health conditions, other medicines and costs. Follow-up should concern response and tolerability, not merely renewal authorization. Neither a detailed contract nor a clear price predicts an individual member’s results.
Questions & answers
Will Found refund me if I cannot receive the GLP-1 I wanted?
Not necessarily. Found distinguishes medical disqualification from all available treatment options from ineligibility for a specific preferred medication. If other Found options remain available, the latter does not qualify for a refund under that provision. The separate early-cancellation membership policy may matter, but its conflicting wording should be clarified before purchase.
Does Found’s $99 semaglutide price continue after the first payment?
It depends on the offer. For a new member’s one-month insured plan, $99 is introductory and then becomes $199 per 28-day cycle. The terms also list $99 for the 12-month insurance plan, while the pricing page ties its lowest rates to upfront payment. Those are different arrangements, and the Medicare page adds another unresolved pricing context.
Does using insurance eliminate separate visit charges?
No. Found says insured care requires synchronous video visits, including before refills, with the applicable visit copay added to the plan price; it describes that copay as typically around $30. Deductibles and coinsurance may also apply. Cash-pay care is usually asynchronous text-based care without a separate visit copay.
How early should I cancel or pause a Found renewal?
Found recommends doing so at least 48 hours before the scheduled renewal because renewal payments are nonrefundable. The consulted documentation does not fully establish cancellation steps or how unused prepaid periods are handled. Confirm the effective date and retain written acknowledgment; cancellation should not be assumed to reverse a charge or stop an already dispensed pharmacy order.
Can I choose the pharmacy for a branded prescription?
Found says branded GLP-1 medication can be filled through a pharmacy of your choice using cash or insurance. Eligible members may instead use NovoCare or LillyDirect, which Found describes as cash-pay-only routes. Medication remains separate from the branded-plan membership charge. Those options do not establish an equivalent pharmacy-choice policy for compounded prescriptions.
Does Found provide immediate human help through its app?
The documentation does not promise that. Found allows care-team messages between visits and describes monthly follow-up for compounded tirzepatide. Its explicitly advertised 24/7 companion is Aimee, an AI tool. Ask about human response times, urgent clinical contact and billing support before enrolling; the public descriptions do not establish one immediate-response channel for every problem.
Our assessment
Found documents a broad service with multiple medication pathways, meaningful follow-up descriptions and detailed price schedules. Its contracts also disclose consequential limits: a preferred prescription is not assured, insurance does not cover every component, renewals are nonrefundable and dispensed or shipped medication cannot be returned. The main weakness is reconciliation between pages, particularly annual prepayment versus 28-day billing, the membership refund window and Medicare-specific offers. Before enrolling, obtain one written, product-specific explanation of the initial payment, subsequent charges, consultation costs, cancellation procedure and unused-prepayment treatment. Found’s public documentation supports evaluating it as a structured weight-management program, but not treating its lowest advertised price as a complete or universally available offer.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Found — medication/compounded tirzepatide ↗
- Found — microdosing ↗
- Found — official website ↗
- Found — medicare weight loss ↗
- Found — medication/compounded semaglutide ↗
- Sesame / Success by Sesame — terms/offer terms v3 ↗
- Sesame / Success by Sesame — glp1 checker ↗
- Sesame / Success by Sesame — plans and pricing ↗
- Sesame / Success by Sesame — insurance ↗
- Sesame / Success by Sesame — terms/payment and billing consent ↗